Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluticasone Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 14/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.78 |
| ▸ | CNR1 | P21554 | 1/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluticasone Propionate SCHEMBL5482829 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL14339613 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL4283 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL15325049 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL13602403 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL13026160 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL14343427 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL15944858 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL191134 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL13993454 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257531-B1 | METHOD FOR THE PREPARATION OF CARBOTHIOIC ACIDS | ABBOTT LAB (US) | 2004-09-15 | — | — | EP | claimed |
| US-20020133032-A1 | Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods | ABBOTT LABORATORIES | 2002-09-19 | — | — | US | claimed |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT INC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT INC (US) | 2023-10-05 | — | — | US | disclosed |
| EP-3901162-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | AbbVie Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| US-10188665-B2 | Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues | ALLERGAN, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180126000-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180125861-A1 | OCULAR THERAPY USING GLUCOCORTICOID DERIVATIVES SELECTIVELY PENETRATING POSTERIOR SEGMENT TISSUES | ALLERGAN, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180125861-A1 | OCULAR THERAPY USING GLUCOCORTICOID DERIVATIVES SELECTIVELY PENETRATING POSTERIOR SEGMENT TISSUES | ALLERGAN, INC. | 2018-05-10 | — | — | US | disclosed |
| WO-2017207776-A1 | SYSTEM FOR DISPENSING A COSMETIC PRODUCT | L'OREAL (FR) | 2017-12-07 | — | — | WO | disclosed |
| US-9820995-B2 | Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues | ALLERGAN, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20090082321-A1 | STEROID CONTAINING DRUG DELIVERY SYSTEMS | ALLERGAN, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-7214807-B2 | Method for the preparation of fluticasone and related 17β-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods | ABBOTT LABORATORIES (US) | 2007-05-08 | — | — | US | disclosed |
| US-7208613-B2 | Synthesis of s-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2007-04-24 | — | — | US | disclosed |
| US-7208613-B2 | Synthesis of s-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2007-04-24 | — | — | US | disclosed |
| US-20070088014-A1 | OCULAR THERAPY USING GLUCOCORTICOID DERIVATIVES SELECTIVELY PENETRATING POSTERIOR SEGMENT TISSUES | ALLERGAN, INC. (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088014-A1 | OCULAR THERAPY USING GLUCOCORTICOID DERIVATIVES SELECTIVELY PENETRATING POSTERIOR SEGMENT TISSUES | ALLERGAN, INC. (US) | 2007-04-19 | — | — | US | disclosed |
| US-20040209854-A1 | Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods | ABBVIE INC. | 2004-10-21 | — | — | US | disclosed |
| EP-1257531-B1 | METHOD FOR THE PREPARATION OF CARBOTHIOIC ACIDS | ABBOTT LAB (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20020133032-A1 | Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods | ABBOTT LABORATORIES | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180126000-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 197/4885AR 87/4885 |
| US-20070088014-A1 | OCULAR THERAPY USING GLUCOCORTICOID DERIVATIVES SELECTIVELY PENETRATING POSTERIOR SEGMENT TISSUES | SERPINA6, NR3C1, PDE6C | NR3C1 2/4885PGR 74/4885AR 450/4885 |
| US-20020133032-A1 | Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods | HSD17B7, CYP17A1, NR5A1 | NR3C1 17/4885PGR 1622/4885AR 498/4885 |
| US-20090082321-A1 | STEROID CONTAINING DRUG DELIVERY SYSTEMS | HSD17B2, HSD17B3, HSD17B7 | NR3C1 5/4885PGR 120/4885AR 584/4885 |
| US-10188665-B2 | Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues | SERPINA6, NR3C1, PDE6C | NR3C1 2/4885PGR 74/4885AR 450/4885 |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | CD47, CLTA, FCGR2A | NR3C1 104/4885PGR 2891/4885AR 1117/4885 |
| US-20040209854-A1 | Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods | HSD17B7, CYP17A1, NR5A1 | NR3C1 17/4885PGR 1622/4885AR 498/4885 |
| US-20180125861-A1 | OCULAR THERAPY USING GLUCOCORTICOID DERIVATIVES SELECTIVELY PENETRATING POSTERIOR SEGMENT TISSUES | SERPINA6, NR3C1, PDE6C | NR3C1 2/4885PGR 74/4885AR 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.